The Inhibitory Effects of a Peripherally Restricted CB1 Receptor Antagonist on Myofibroblast Transdifferentiation of Human Retinal Pigment Epithelial Cells
Cells · 2026
DOI: 10.3390/cells15050418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Dandan Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292, USA. Hauptthemen laut MEDLINE: Cell Transdifferentiation, Myofibroblasts, Receptor, Cannabinoid, CB1, Retinal Pigment Epithelium. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, National Institute of Health, Prevent Blindness (RPB) New Chair Challenge Grant.
Abstract (Originalsprache)
Myofibroblasts derived from retinal pigment epithelial (RPE) cells play a key role in the pathogenesis of retinal fibrotic conditions such as proliferative vitreoretinopathy (PVR). Upon exposure to growth factors and cytokines such as TNF-α and TGF-β (TNT), RPE cells undergo epithelial-mesenchymal transition and subsequent transdifferentiation to contractile myofibroblasts. In this study, the effects of JD5037, a peripherally restricted CB1 antagonist, on myofibroblast transdifferentiation of primary cultures of human RPE cells were assessed. JD5037 significantly reduced TNT-induced, RPE cell-mediated collagen gel contraction, an indicator of myofibroblast function, in a concentration-dependent manner. Western blot analysis showed that JD5037 attenuated TNT-induced expression of α-SMA and fibronectin, two molecular markers of myofibroblasts. Furthermore, siRNA knockdown of CB1 cannabinoid receptor partially inhibited TNT-induced myofibroblast transdifferentation of human RPE cells and eliminated the inhibitory effects of JD5037 on myofibroblast transdifferentiation. These data demonstrate, for the first time, that peripherally restricted antagonists, such as JD5037, targeting the CB1 cannabinoid receptor have therapeutic potential for PVR and other retinal fibrotic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292, USA.
- Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Louisville, KY 40292, USA.
- Eye Hospital of China Academy of Chinese Medical Sciences, Beijing 100040, China.
- Department of Ophthalmology and Visual Sciences, Ohio State University College of Medicine, Columbus, OH 43210, USA.
ORCID-Profile: Vishaka Motheramgari
Förderung
- NEI NIH HHS
- National Institute of Health
- Prevent Blindness (RPB) New Chair Challenge Grant
Zitieren
APA
Zhao, D., Motheramgari, V., Shrader, S. H., Wang, W., Tamiya, S., & Song, Z. H. (2026). The Inhibitory Effects of a Peripherally Restricted CB1 Receptor Antagonist on Myofibroblast Transdifferentiation of Human Retinal Pigment Epithelial Cells. Cells. https://doi.org/10.3390/cells15050418
Vancouver
Zhao D, Motheramgari V, Shrader SH, Wang W, Tamiya S, Song ZH. The Inhibitory Effects of a Peripherally Restricted CB1 Receptor Antagonist on Myofibroblast Transdifferentiation of Human Retinal Pigment Epithelial Cells. Cells. 2026. doi:10.3390/cells15050418
BibTeX
@article{Zhao2026,
author = {Zhao, Dandan and Motheramgari, Vishaka and Shrader, Sarah H and Wang, Wei and Tamiya, Shigeo and Song, Zhao-Hui},
title = {The Inhibitory Effects of a Peripherally Restricted CB1 Receptor Antagonist on Myofibroblast Transdifferentiation of Human Retinal Pigment Epithelial Cells},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15050418}
}
EUVIMED